Welcome!

News Feed Item

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

Summary

Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.

While there are significant barriers facing this market, current and future players can still position themselves to obtain a competitive advantage. The major European countries included in this forecast have general mass screening programs for breast cancer detection and they will be increasing their adoption of more expensive VAB devices. Additionally, the emerging economies will see an increased shift from fine needle aspiration devices to more expensive core biopsy devices over the forecast.

Scope

- An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019.
- Investigation of current and future market competition for biopsy devices
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the biopsy devices sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL).

Reasons to buy

- Understand the trends shaping and driving EU biopsy devices Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in EU biopsy devices market through 2019.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in EU biopsy devices market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Overview 14
2.2 Catalyst 15
2.3 Related Reports 15
3 Industry Overview 16
3.1 Types of Biopsies 16
3.1.1 Surgical Biopsy 16
3.1.2 Fine Needle Aspiration 16
3.1.3 Core Needle Biopsy 17
3.1.4 Vacuum-Assisted Biopsy 18
3.2 Biopsy Procedure Trends 18
3.2.1 EU 18
3.3 Market Access to Cancer Screening Programs 24
3.3.1 Regulation 24
3.3.2 Biopsy Device Adoption Patterns 27
3.3.3 Reimbursement Trends 31
3.4 Regulatory Issues/Recalls 33
3.5 Mergers & Acquisitions/Key Partnerships 34
3.5.1 Hologic Acquires Suros Surgical Systems 34
3.5.2 C. R. Bard Acquires SenoRx 34
3.5.3 Devicor Medical Products Acquires Breast Care Portfolio from Ethicon Endo-Surgery 34
3.6 Economic Impact of Cancer Screening and Treatment 35
3.7 Additional Indications for Biopsy Devices 36
4 Unmet Needs 37
4.1 Overview 37
4.2 More Efficient Screening Tests for Prostate Cancer 37
4.3 More Efficient Screening Tests for Breast Cancer 38
4.4 More Efficient Screening Guidelines for Thyroid Cancer 38
4.5 Screening Tests That Can Provide Histological Analysis In Situ 39
5 Market Opportunity Analysis 40
5.1 Increase Marketing for Vacuum-Assisted Biopsy Devices in European Countries 40
5.2 Bundling Solutions 41
5.3 Focus Efforts on China's Increasing Adoption of VAB Devices 42
5.4 Market for Prostate Cancer Screening Coverage in Europe 42
6 Market Drivers and Barriers 44
6.1 Market Drivers 44
6.1.1 Inadequate Screening Tests for Particular Cancers 44
6.1.2 Demand for Minimally-Invasive Biopsy Techniques 45
6.1.3 Increased Adherence to Certain Cancer Screening Guidelines 45
6.1.4 Aging Patient Population 46
6.2 Market Barriers 47
6.2.1 Increased Competition from Other Cancer Diagnostic Tests 47
6.2.2 Breast Biopsy Reimbursement Bundling 50
6.2.3 Decreased Adherence to Certain Cancer Screening Guidelines 52
6.2.4 Benefits of Mass Prostate Cancer Screening Being Outweighed by Risks 53
7 Competitive Assessment 55
7.1 Overview 55
7.2 Classification Based on System 55
7.2.1 Vacuum-Assisted Biopsy Devices 55
7.2.2 Core Needle Biopsy Devices 57
7.2.3 Fine Needle Aspiration Devices 58
8 Pipeline Assessment 60
8.1 Overview 60
8.1.1 Optical Biopsy 61
8.1.2 Liquid Biopsy 62
9 Clinical Trial Analysis 63
10 Current and Future Players 65
10.1 Trends in Corporate Strategy 65
10.2 Company Profiles 65
10.2.1 Argon Medical Devices 65
10.2.2 Boston Scientific 68
10.2.3 Cardinal Health 71
10.2.4 CareFusion Corporation 72
10.2.5 Cook Medical 74
10.2.6 C. R. Bard 77
10.2.7 Devicor Medical Products 83
10.2.8 DTR Medical 87
10.2.9 Gallini Medical Devices 88
10.2.10 Hologic 91
10.2.11 INRAD 94
10.2.12 Intact Medical Corporation 96
10.2.13 TSK Laboratory 98
11 Market Outlook 100
11.1 Company Market Share 100
11.1.1 Vacuum-Assisted Biopsy Market Share 100
11.1.2 Core Needle Biopsy/Fine Needle Aspiration Market Share 102
11.2 By Segment 103
11.2.1 Fine Needle Aspiration 103
11.2.2 Core Needle Biopsy 104
11.2.3 Vacuum-Assisted Biopsy 105
11.3 By Geography 106
11.3.1 France 106
11.3.2 Germany 107
11.3.3 Italy 109
11.3.4 Spain 110
11.3.5 United Kingdom 112
12 Appendix 114
12.1 Bibliography 114
12.2 Abbreviations 123
12.3 Report Methodology 125
12.3.1 Overview 125
12.3.2 Coverage 125
12.3.3 Primary Research 125
12.3.4 Secondary Research 126
12.3.5 Forecasting Methodology 127
12.4 Key Opinion Leaders Included in This Study 127
12.5 About the Authors 128
12.5.1 Joseph A. Gregory, Analyst, Surgical Devices 128
12.5.2 Derek Archila, MBA, Director of Research and Analysis, Medical Devices 128
12.6 Global Head of Healthcare 129
12.6.1 Bonnie Bain, Ph.D., Global Head of Healthcare 129
12.7 About MediPoint 130
12.8 About GlobalData 130
12.9 Disclaimer 130

List of Tables

Table 1: Breast Cancer Incidence Rates, 5EU, 2010-2019 21
Table 2: Biopsy Device Adoption Patterns in Diagnosing Prostate Cancer, Global, 2013 and 2019 28
Table 3: Biopsy Device Adoption Patterns in Diagnosing Breast Cancer, Global, 2013 and 2019 29
Table 4: Biopsy Device Adoption Patterns in Diagnosing Lung Cancer, Global, 2013 and 2019 30
Table 5: Biopsy Device Adoption Patterns in Diagnosing Liver Cancer, Global, 2013 and 2019 30
Table 6: Biopsy Device Adoption Patterns in Diagnosing Thyroid Cancer, Global, 2013 and 2019 31
Table 7: Age Demographics, Age >65 Years, Global, 2013 46
Table 8: Stereotactic Breast Biopsy Ambulatory Surgery Center Billing, 2011 51
Table 9: Stereotactic Breast Biopsy Physician Billing, 2011 51
Table 10: Company Profile - Argon Medical Devices 66
Table 11: Product Portfolio - Argon Medical Devices 67
Table 12: Argon Medical Devices, SWOT Analysis, 2013 67
Table 13: Company Profile - Boston Scientific 68
Table 14: Product Portfolio - Boston Scientific 70
Table 15: Boston Scientific SWOT Analysis, 2013 70
Table 16: Company Profile - Cardinal Health 71
Table 17: Product Portfolio - Cardinal Health 72
Table 18: Cardinal Health SWOT Analysis, 2013 72
Table 19: Company Profile - CareFusion Corporation 73
Table 20: Product Portfolio - CareFusion 74
Table 21: CareFusion, SWOT Analysis, 2013 74
Table 22: Company Profile - Cook Medical 75
Table 23: Product Portfolio - Cook Medical 76
Table 24: Cook Medical, SWOT Analysis, 2013 77
Table 25: Company Profile - C. R. Bard 78
Table 26: Product Portfolio - C. R. Bard 78
Table 27: C.R. Bard, SWOT Analysis, 2013 82
Table 28: Company Profile - Devicor Medical Products 83
Table 29: Product Portfolio - Devicor Medical Products 86
Table 30: Devicor Medical Products SWOT Analysis, 2013 86
Table 31: Company Profile - DTR Medical 87
Table 32: Product Portfolio - DTR Medical 87
Table 33: DTR Medical SWOT Analysis, 2013 88
Table 34: Company Profile - Gallini Medical Devices 89
Table 35: Product Portfolio - Gallini Medical Devices 90
Table 36: Gallini Medical Devices SWOT Analysis, 2013 90
Table 37: Company Profile - Hologic 91
Table 38: Product Portfolio - Hologic 93
Table 39: Hologic SWOT Analysis, 2013 93
Table 40: Company Profile - INRAD 94
Table 41: Product Portfolio - INRAD 95
Table 42: INRAD SWOT Analysis, 2013 95
Table 43: Company Profile - Intact Medical Corporation 96
Table 44: Product Portfolio - Intact Medical Corporation 97
Table 45: Intact Medical Corporation SWOT Analysis, 2013 97
Table 46: Company Profile - TSK Laboratory 98
Table 47: Product Portfolio - TSK Laboratory 99
Table 48: TSK Laboratory SWOT Analysis, 2013 99
Table 49: VAB, Global Market Share, 2013 101
Table 50: CNB/FNA, Global Market Share, 2013 102
Table 51: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Table 52: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Table 53: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Table 54: France Biopsy Devices Sales ($m) Forecast, 2010-2019 106
Table 55: Germany Biopsy Devices Sales ($m) Forecast, 2010-2019 108
Table 56: Italy Biopsy Devices Sales ($m) Forecast, 2010-2019 109
Table 57: Spain Biopsy Devices Sales ($m) Forecast, 2010-2019 111
Table 58: United Kingdom Biopsy Devices Sales ($m) Forecast, 2010-2019 112

List of Figures

Figure 1: Biopsy Procedure Volumes: Prostate, 5EU, 2010-2019 19
Figure 2: Biopsy Procedure Volumes: Breast, 5EU, 2010-2019 20
Figure 3: Biopsy Procedure Volumes: Lung, 5EU, 2010-2019 22
Figure 4: Biopsy Procedure Volumes: Liver, 5EU, 2010-2019 23
Figure 5: Biopsy Procedure Volumes: Thyroid, 5EU, 2010-2019 24
Figure 6: EnCor Breast Biopsy System 79
Figure 7: EnCor Enspire Breast Biopsy System 80
Figure 8: EnCor Ultra Breast Biopsy System 80
Figure 9: Finesse Ultra Breast Biopsy System 81
Figure 10: Vacora Breast Biopsy System 82
Figure 11: Original Mammotome System 84
Figure 12: Mammotome Elite 85
Figure 13: Mammotome Revolve 86
Figure 14: VAB, Global Market Share, 2013 101
Figure 15: CNB/FNA, Global Market Share, 2013 102
Figure 16: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Figure 17: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Figure 18: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Figure 19: France Biopsy Devices Sales ($) Forecast, 2010-2019 107
Figure 20: Germany Biopsy Devices Sales ($) Forecast, 2010-2019 108
Figure 21: Italy Biopsy Devices Sales ($) Forecast, 2010-2019 110
Figure 22: Spain Biopsy Devices Sales ($) Forecast, 2010-2019 111
Figure 23: United Kingdom Biopsy Devices Sales ($) Forecast, 2010-2019 113

Read the full report:
MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection. In his session at 18th Cloud Expo, Bradley Holt, a Developer Advocate with IBM Cloud Data Services, discussed...
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...